A medchem minilecture on the 'Novel Psilocin Prodrugs with Altered Pharmacological Properties as Candidate Therapies for Treatment-Resistant Anxiety Disorders' by S. A. Raithatha, J. M. Hagel, K. Matinkhoo, L. Yu, D. Press, S. G. Cook, G. Sharma, D. Dhananjaya, G. Jensen, J. B. Lee, C. Cai, J. Gallant, J. Bains, J. E. Tucker, and P. J. Facchini*. It explains the metabolism of psilocybin, how this can be modified to produce more active prodrugs and the biological studies used to demonstrate the novel compounds psychedelic and medicinal effects. The chemical synthesis of psilocin is explained along with strategies to modify the structure to modulate its pharmacokinetic properties.



SUPPORT THE CHANNEL ON PATREON:
[ Ссылка ]

NMR Spectroscopy in music:
J. New Music Res. 2021, 50:5, 487-501

Socials:
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]


References:
J. Med. Chem. 2024, 67, 2, 1024–1043 (This work)
Clin. Pharmacokinet. 2017, 56,1543−1554 (Psilocybin Metabolism)
Pharm. Acta Helv. 1997, 72, 175−184 (Psilocybin Metabolism)
Psychopharmacology 2013, 227, 727−739 (Head Twitch Response)
Neuropharmacology 2020, 167, No. 107933 (Head Twitch Response)
ACS Chem. Neurosci. 2013, 4, 33−42 (Head Twitch Response)

свернуть